Brief Article
Copyright ©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 7, 2013; 19(29): 4791-4798
Published online Aug 7, 2013. doi: 10.3748/wjg.v19.i29.4791
Table 4 Adverse events in the four treatment groups n (%)
Adverse eventsGroup
Cs (n = 43)Cc (n = 43)Ns (n = 41)Nc (n = 41)
Hypoxemia (SpO2 < 90% for ≥ 15 s)4 (9.3)a12 (27.9)3 (7.3)5 (12.2)
SpO2 89%-80%2 (4.7)5 (11.2)2 (4.9)3 (7.3)
SpO2 79%-60%2 (4.7)5 (11.2)1 (2.4)2 (4.9)
SpO2 59%-40%0 (0.0)1 (2.3)0 (0.0)0 (0.0)
SpO2 < 40%0 (0.0)1 (2.3)0 (0.0)0 (0.0)
Average decrease in value of SpO22.3 ± 5.4a7.3 ± 12.61.7 ± 4.32.6 ± 5.8
Hypotension (SBP < 90 mmHg or DBP < 60 mmHg)0 (0.0) 1 (2.3)0 (0.0)0 (0.0)
Extent of SBP decrease
≤ 1028 (65.1)17 (39.5)34 (82.9)28 (68.3)
11-2015 (34.9)a26 (60.5)7 (17.1)13 (31.7)
> 200 (0.0)0 (0.0)0 (0.0)0 (0.0)
Average decrease in value of SBP10.4 ± 3.3b15.1 ± 6.810.2 ± 3.310.6 ± 4.5
Extent of DBP decrease
≤ 1040 (93.0)34 (79.1)37 (90.2)38 (92.7)
11-203 (7.0)9 (20.9)4 (9.8)3 (7.3)
> 200 (0.0)0 (0.0)0 (0.0)0 (0.0)
Average decrease in value of DBP7.9 ± 2.2b9.5 ± 1.87.6 ± 2.68.0 ± 1.7
Tachycardia (> 100 bpm)3 (7.0)2 (4.7)2 (4.9)1 (2.4)
Bradycardia (< 60 bpm)3 (7.0)6 (14.0)3 (7.3)4 (9.8)
Decrease of pulse rate33 (76.7)36 (83.7)29 (70.7)28 (68.3)
Increase of pulse rate8 (18.6)6 (14.0)8 (19.5)8 (19.5)
No change of pulse rate2 (4.7)1 (2.3)4 (9.8)5 (12.2)
Average change in value of pulse rate0.6 ± 2.8a2.2 ± 2.80.7 ± 2.41.4 ± 2.5
Arrhythmias2 (4.7)1 (2.3)1 (2.4)0 (0.0)
Other adverse events3 (7.0)5 (11.6)2 (4.9)3 (7.3)
Extrapyramidal reactions0 (0.0) 1 (2.3)0 (0.0)0 (0.0)
Somnolence1 (2.3)2 (4.7)1 (2.4)1 (2.4)
Dizziness2 (4.7)2 (4.7)1 (2.4)2 (4.9)
Overall rate of adverse events15 (34.9)b27 (62.8)11 (26.8)13 (31.7)